

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

HUMAN TNF ALPHA (N-6HIS) PROTEIN

Cat.#: 12039

Product Name: Human TNF Alpha (N-6His) Protein

Size: 10 µg, 50 µg and 100 µg

Synonyms: Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis

Factor Ligand Superfamily Member 2;TNF-a;TNF;TNFA;TNFSF2

Target: TNF

UNIPROT ID: P01375

Description: Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding

Gly57-Leu233 is expressed with a 6His tag at the N-terminus.

Background: Tumor Necrosis Factor-a (TNF-a) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-a while cells that express CD8 secrete little or no TNF-a. Synthesis of TNF-a can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-a has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-a that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-a mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-a High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.

Species/Host: E.coli

Molecular Weight: 21.8 KDa

Molecular Characterization: Not available

Purity: Greater than 95% as determined by reducing SDS-PAGE.

Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010

Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.